HRP20200315T1 - Čvrsti oralni pripravci na bazi soli s-adenozilmetionina i postupak njihove priprave - Google Patents
Čvrsti oralni pripravci na bazi soli s-adenozilmetionina i postupak njihove priprave Download PDFInfo
- Publication number
- HRP20200315T1 HRP20200315T1 HRP20200315TT HRP20200315T HRP20200315T1 HR P20200315 T1 HRP20200315 T1 HR P20200315T1 HR P20200315T T HRP20200315T T HR P20200315TT HR P20200315 T HRP20200315 T HR P20200315T HR P20200315 T1 HRP20200315 T1 HR P20200315T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- preparation
- adenosylmethionine
- relation
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 12
- 238000000034 method Methods 0.000 title claims 10
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 18
- NWVICASORGOGDW-FFSFXTILSA-N [(3s)-3-amino-3-carboxypropyl]-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium;butane-1,4-disulfonate Chemical compound [O-]S(=O)(=O)CCCCS([O-])(=O)=O.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1.O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NWVICASORGOGDW-FFSFXTILSA-N 0.000 claims 7
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims 7
- 239000000292 calcium oxide Substances 0.000 claims 7
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims 7
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 235000012209 glucono delta-lactone Nutrition 0.000 claims 2
- 239000000182 glucono-delta-lactone Substances 0.000 claims 2
- 229960003681 gluconolactone Drugs 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- DATAGRPVKZEWHA-UHFFFAOYSA-N l-theanine Chemical compound CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims 2
- 239000000395 magnesium oxide Substances 0.000 claims 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
- 235000012245 magnesium oxide Nutrition 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 2
- 229960003987 melatonin Drugs 0.000 claims 2
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000002966 varnish Substances 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000019568 aromas Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 229960000869 magnesium oxide Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Claims (17)
1. Pripravak, naznačen time što sadrži S-adenozilmetionin-sulfat-para-toluensulfonat ili S-adenozilmetionin-1,4-butan-disulfonat u smjesi s kalcijevim oksidom i izborno farmaceutski prihvatljive pomoćne tvari.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je S-adenozilmetionin-sulfat-para-toluensulfonat ili S-adenozilmetionin-1,4-butan-disulfonat u njemu prisutan u količini koja se kreće od 30 do 90%, težinski, u odnosu na težinu pripravka, po mogućnosti od 50 do 85%, težinski, u odnosu na težinu pripravka.
3. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je kalcijev oksid u njemu prisutan u količini koja se kreće od 1 do 40%, težinski, u odnosu na težinu pripravka, po mogućnosti od 2 do 20%, težinski, u odnosu na težinu pripravka.
4. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži najmanje jedan dodatni aktivni sastojak, kojeg se po mogućnosti bira između l-melatonina, l-teanina i/ili l-triptofana i/ili 5-hidroksitriptofana ili njihove smjese.
5. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je najmanje jedna od farmaceutski prihvatljivih pomoćnih tvari kalcijev sulfat hemihidrat i/ili glukono-δ-lakton.
6. Pripravak u skladu s prethodnim patentnim zahtjevima, naznačen time što je u obliku izravne smjese, tablete, kapsule, granulata ili praha, po mogućnosti u obliku tablete, poželjnije obične, obložene, filmom obložene i/ili želučanootporne tablete.
7. Postupak priprave tablete u skladu s patentnim zahtjevom 6, naznačen time što se sastoji u sljedećim koracima:
a) miješanja S-adenozilmetionin-sulfat-para-toluensulfonata ili S-adenozilmetionin-1,4-butan-disulfonata s kalcijevim oksidom i farmaceutski prihvatljivim pomoćnim tvarima,
b) predkomprimiranja i naknadno granuliranje smjese dobivene u koraku a),
c) miješanja granulata dobivenog u koraku b) s farmaceutski prihvatljivim pomoćnim tvarima, poput kalcijevog sulfata hemihidrata, ksilitola, jabučne kiseline, glutaminske kiseline, glukono-δ-laktona, magnezijevog oksida, hidrogeniranih masnih kiselina, istaloženog silicijevog dioksida, magnezijevog stearata, saharoze, glicerol-behenata,
d) komprimiranja smjese dobivene u koraku c), uz izborno dodavanje sladila i/ili aroma,
e) izbornog oblaganja tablete dobivene u koraku d) hidrogeniranim masnim kiselina,
f) izbornog oblaganja tablete dobivene u koraku e) filmom u vodenoj fazi.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se u koraku c) najmanje jedan dodatni aktivni sastojak, kojeg se po mogućnosti bira između l-melatonina, l-teanina i/ili l-triptofana i/ili 5-hidroksitriptofana i/ili njihovih smjesa može dodati u smjesu.
9. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se oblaganje spomenuto u koraku e) primijenjuje upotrebom hidrogeniranih masnih kiselina u količini između 0,4 i 1,5%, težinski, u odnosu na težinu tablete.
10. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se stvaranje filma u vodenoj fazi spomenuto u koraku f) provodi uz upotrebu laka, kojeg se po mogućnosti bira između gumenog laka i/ili njegovih soli (Shellac™), metakriline kiseline, celuloznih acetoftalata, titanijevog dioksida, talka, trietil-citrata, PVP K30, kurkumina, luteina, hidroksipropilceluloze, hidroksipropilmetilceluloze i/ili njihovih smjesa.
11. Pripravci, naznačeni time što ih se može pripraviti postupkom u skladu s patentnim zahtjevima 7-10.
12. Upotreba S-adenozilmetionin-sulfat-para-toluensulfonata ili S-adenozilmetionin-1,4-butan-disulfonata u smjesi s kalcijevim oksidom, naznačena time što je navedena smjesa namijenjena pripravi pripravka za liječenje depresivnih stanja.
13. Upotreba u skladu s patentnim zahtjevom 12, naznačen time što se magnezijev oksid dodatno dodaje navedenom kalcijevom oksidu.
14. Postupak stabiliziranja pripravka na bazi S-adenozilmetionin-sulfat-para-toluensulfonata ili S-adenozilmetionin-1,4-butan-disulfonata, naznačen time što se sastoji u upotrebi smjese S-adenozilmetionin-sulfat-para-toluensulfonata ili S-adenozilmetionin-1,4-butan-disulfonata s kalcijevim oksidom.
15. Postupak u skladu s patentnim zahtjevom 14, naznačen time što je S-adenozilmetionin-sulfat-para-toluensulfonat ili S-adenozilmetionin-1,4-butan-disulfonat u njemu prisutan u količini između 30 i 90%, težinski, izračunato u odnosu na težinu pripravka, po mogućnosti između 50 i 85%, težinski, izračunato u odnosu na težinu pripravka.
16. Postupak u skladu s patentnih zahtjeva 14-15, naznačen time što je kalcijev oksid u njemu prisutan u količini koja se kreće od 1 do 40%, težinski, u odnosu na težinu pripravka, po mogućnosti od 2 do 20%, težinski, u odnosu na težinu pripravka.
17. Postupak u skladu s patentnim zahtjevom 16, naznačen time što se sastoji u dodavanju farmaceutski prihvatljivih pomoćnih tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000629A ITMI20060629A1 (it) | 2006-03-31 | 2006-03-31 | Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento |
| PCT/IT2006/000610 WO2007113885A2 (en) | 2006-03-31 | 2006-08-08 | Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them |
| EP06780609.1A EP2007479B1 (en) | 2006-03-31 | 2006-08-08 | Solid oral compositions based on S-adenosyl methionine salt and process for obtaining them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200315T1 true HRP20200315T1 (hr) | 2020-06-12 |
Family
ID=37327762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200315TT HRP20200315T1 (hr) | 2006-03-31 | 2020-02-25 | Čvrsti oralni pripravci na bazi soli s-adenozilmetionina i postupak njihove priprave |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20090110729A1 (hr) |
| EP (1) | EP2007479B1 (hr) |
| JP (1) | JP5562632B2 (hr) |
| CN (1) | CN101415464B (hr) |
| AU (1) | AU2006341243B2 (hr) |
| BR (1) | BRPI0621556B8 (hr) |
| CA (1) | CA2645767C (hr) |
| DK (1) | DK2007479T3 (hr) |
| EA (1) | EA017895B1 (hr) |
| ES (1) | ES2774913T3 (hr) |
| HR (1) | HRP20200315T1 (hr) |
| HU (1) | HUE047955T2 (hr) |
| IL (1) | IL194254A (hr) |
| IT (1) | ITMI20060629A1 (hr) |
| ME (2) | MEP22708A (hr) |
| MX (1) | MX2008012491A (hr) |
| NZ (1) | NZ571240A (hr) |
| PL (1) | PL2007479T3 (hr) |
| RS (2) | RS59995B1 (hr) |
| SI (1) | SI2007479T1 (hr) |
| WO (1) | WO2007113885A2 (hr) |
| ZA (1) | ZA200808118B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| GEP20156209B (en) | 2008-08-15 | 2015-01-12 | Aironvud Farmasiutikalz Ink | Linaclotide-containing formulations for oral administration |
| EP2189154A1 (en) | 2008-11-25 | 2010-05-26 | Gnosis S.p.A. | Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof |
| IT1393331B1 (it) * | 2009-02-09 | 2012-04-20 | Graal S R L | Composizioni orosolubili e/o effervescenti contenenti almeno un sale di s-adenosilmetionina (same) |
| WO2012012902A1 (en) * | 2010-07-28 | 2012-02-02 | Msi Methylation Sciences Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
| US8329208B2 (en) * | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
| CA2770077A1 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| ES2638589T3 (es) | 2010-02-17 | 2017-10-23 | Ironwood Pharmaceuticals, Inc. | Tratamientos para trastornos intestinales |
| ES2763404T3 (es) | 2010-08-11 | 2020-05-28 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
| EA015508B1 (ru) * | 2011-03-03 | 2011-08-30 | Екофарм Патент Менеджмент Аг | Фармацевтическая композиция, стимулирующая биосинтез s-аденозилметионина, и пероральное лекарственное средство |
| TR201103625A1 (tr) * | 2011-04-14 | 2012-12-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Sefuroksim içeren tablet formülasyonu üretim prosesi. |
| US9708371B2 (en) | 2011-08-17 | 2017-07-18 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| ITMI20131906A1 (it) * | 2013-11-18 | 2015-05-19 | Gnosis Spa | Composizioni solide orali a lento rilascio |
| ES2775734T3 (es) * | 2015-08-31 | 2020-07-28 | Nutramax Lab Inc | Composiciones que comprenden magnolia, felodendron, teanina y/o proteína de suero |
| IT202000006127A1 (it) * | 2020-03-23 | 2021-09-23 | Fmc S R L | Formulazione farmaceutica, dietetica e/o alimentare a base ademetionina e processo di realizzazione di detta formulazione |
| CN115708820B (zh) * | 2023-01-09 | 2023-06-02 | 广东科泰鼎润药业科技有限公司 | L-茶氨酸缓释制剂、双释放制剂、应用和药物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3012943A (en) * | 1958-11-18 | 1961-12-12 | Nutrilite Products | Vitamin c concentrate |
| US3330729A (en) * | 1963-10-04 | 1967-07-11 | Goodrich Co B F | Sustained release tablet containing medicament admixed in a waterinsoluble acrylic acid cross-linked polymer and selected basic magnesium or calcium diluent |
| IE37913B1 (en) * | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
| IE39517B1 (en) * | 1973-06-27 | 1978-10-25 | Bioresearch Sas | Double salts of s-adenosyl-l-methhionine |
| AR221676A1 (es) * | 1974-07-12 | 1981-03-13 | Bioresearch Sas | Procedimiento para la preparacion de sales estables sulfonicas y/o sulfuricas de la s-adenosil-l-metionina,particularmente utiles como donadores especificos de metilo para las reacciones bioquimicas de transferencia del grupo ch3;asi como tambien las reacciones fundamentales en el metabolismo lipilico,protilico y glucidico |
| CA1187388A (en) * | 1978-09-20 | 1985-05-21 | American Monitor Corporation | Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays |
| GB2064523B (en) * | 1979-12-04 | 1983-06-29 | Kanegafuchi Chemical Ind | Stable composition of s-adenosyl-l-methionine |
| US4394449A (en) * | 1980-02-13 | 1983-07-19 | Modrovich Ivan Endre | Stabilization of coenzymes in aqueous solution |
| IT1137640B (it) * | 1981-08-24 | 1986-09-10 | Bioresearch Srl | Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo |
| IT1139974B (it) * | 1981-09-11 | 1986-09-24 | Bioresearch Srl | Derivati della s-adenosilmetionina,processo per la preparazione e composizioni terapeutiche che li contengono come principio attivo |
| JPS60181095A (ja) * | 1984-02-27 | 1985-09-14 | Nippon Zeon Co Ltd | Ｓ−アデノシル−ｌ−メチオニン含有組成物及びその製造法 |
| IT1173991B (it) * | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Composizioni farmaceutiche comprendenti solfo-afenosil-l-metionina (same) particolarmente adatte per uso orale e per supposte |
| IT1173990B (it) * | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale |
| US4870059A (en) * | 1985-11-27 | 1989-09-26 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Dehydration of hydrous matter with anhydrous maltose |
| US4704365A (en) * | 1986-02-24 | 1987-11-03 | Abbott Laboratories | Composition and method for stabilization of dinucleotides |
| JPH0291018A (ja) * | 1988-09-27 | 1990-03-30 | Farval Ag | 湿気に対して安定な固形バルプロ酸製剤とその製造法 |
| US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
| IT1243859B (it) * | 1990-10-23 | 1994-06-28 | Bioresearch Spa | Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids. |
| US5332727A (en) * | 1993-04-29 | 1994-07-26 | Birkmayer U.S.A. | Stable, ingestable and absorbable NADH and NADPH therapeutic compositions |
| GB2341798B (en) * | 1998-09-25 | 2001-03-14 | Brian Whittle Associates Ltd | Nutritional and pharmaceutical compositions comprising desiccants |
| IT1318535B1 (it) * | 2000-05-25 | 2003-08-27 | Chementecno Srl | Processo per la preparazione di sali farmaceuticamente accettabili di(ss,rs)-s-adenosil-l-metionina. |
| US20020132780A1 (en) * | 2001-01-12 | 2002-09-19 | Heisey Matthew Thomas | Low carbohydrate compositions, kits thereof, and methods of use |
| US20030069202A1 (en) * | 2000-06-02 | 2003-04-10 | Kern Kenneth Norman | Compositions, kits, and methods for promoting defined health benefits |
| WO2002089823A1 (fr) * | 2001-04-27 | 2002-11-14 | Kyoto Pharmaceutical Industries, Ltd. | Methode de conservation pour un suppositoire |
| WO2002102823A1 (en) | 2001-06-14 | 2002-12-27 | Orchid Chemicals & Pharmaceuticals Limited | Stable salts of s-adenosyl-l-methionine (same) and the process for their preparation |
| BRPI0211842B1 (pt) * | 2001-08-10 | 2018-04-03 | Hayashibara Co., Ltd. | Associado cristalino compreendendo trealose e cloreto de cálcio e composição que o compreende |
| ITMI20012462A1 (it) * | 2001-11-22 | 2003-05-22 | Gnosis Srl | Processo per la preparazione di compresse comprendenti s-adenosilmetionina |
| US20040131805A1 (en) * | 2002-06-20 | 2004-07-08 | Merical Rick L. | Films having a desiccant material incorporated therein and methods of use and manufacture |
| EP1671636A4 (en) * | 2003-09-22 | 2009-05-27 | Nisshin Kyorin Pharmaceutical | IMPROVED FIXED 5-AMINOSALICYLIC ACID PREPARATION AND STORAGE METHOD FOR TREATING THEREOF |
| EP1729766A1 (en) * | 2004-03-01 | 2006-12-13 | LEK Pharmaceuticals D.D. | Pharmaceutical formulation |
| CN1663567A (zh) * | 2004-03-05 | 2005-09-07 | 罗靖 | 复方甲硫氨酸维生素b1冻干粉针制剂及其制备方法 |
| US8263574B2 (en) * | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
| ITRM20050344A1 (it) | 2005-06-30 | 2007-01-01 | Luca Maria De | Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi. |
| US20170312207A1 (en) * | 2014-11-10 | 2017-11-02 | Showa Denko K.K. | Moisturizing agent |
-
2006
- 2006-03-31 IT IT000629A patent/ITMI20060629A1/it unknown
- 2006-08-08 EA EA200802095A patent/EA017895B1/ru unknown
- 2006-08-08 JP JP2009502342A patent/JP5562632B2/ja active Active
- 2006-08-08 CA CA2645767A patent/CA2645767C/en active Active
- 2006-08-08 RS RS20200221A patent/RS59995B1/sr unknown
- 2006-08-08 BR BRPI0621556A patent/BRPI0621556B8/pt active IP Right Grant
- 2006-08-08 PL PL06780609T patent/PL2007479T3/pl unknown
- 2006-08-08 ME MEP-227/08A patent/MEP22708A/xx unknown
- 2006-08-08 ME MEP-2008-227A patent/ME00115B/me unknown
- 2006-08-08 CN CN2006800541063A patent/CN101415464B/zh active Active
- 2006-08-08 EP EP06780609.1A patent/EP2007479B1/en active Active
- 2006-08-08 SI SI200632369T patent/SI2007479T1/sl unknown
- 2006-08-08 HU HUE06780609A patent/HUE047955T2/hu unknown
- 2006-08-08 AU AU2006341243A patent/AU2006341243B2/en active Active
- 2006-08-08 RS RSP-2008/0441A patent/RS20080441A/sr unknown
- 2006-08-08 ZA ZA200808118A patent/ZA200808118B/xx unknown
- 2006-08-08 ES ES06780609T patent/ES2774913T3/es active Active
- 2006-08-08 WO PCT/IT2006/000610 patent/WO2007113885A2/en active Search and Examination
- 2006-08-08 DK DK06780609.1T patent/DK2007479T3/da active
- 2006-08-08 NZ NZ571240A patent/NZ571240A/en not_active IP Right Cessation
- 2006-08-08 MX MX2008012491A patent/MX2008012491A/es active IP Right Grant
-
2008
- 2008-09-22 IL IL194254A patent/IL194254A/en active IP Right Grant
- 2008-09-29 US US12/240,002 patent/US20090110729A1/en not_active Abandoned
-
2015
- 2015-05-21 US US14/718,789 patent/US10471088B2/en active Active
-
2020
- 2020-02-25 HR HRP20200315TT patent/HRP20200315T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200315T1 (hr) | Čvrsti oralni pripravci na bazi soli s-adenozilmetionina i postupak njihove priprave | |
| JP6530845B2 (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法 | |
| KR101682965B1 (ko) | 구강내 붕괴성 피복 정제 | |
| JP5827299B2 (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物 | |
| ES2437072T5 (es) | Preparación sólida | |
| CA2874779C (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
| US20150366810A1 (en) | Sustained-release solid preparation for oral use | |
| JP5697668B2 (ja) | 口腔内崩壊錠剤 | |
| JP2019504094A (ja) | 有機化合物のガレヌス製剤 | |
| CA2599649C (en) | Drug formulations having controlled bioavailability | |
| ES2700364T3 (es) | Comprimido de disgregación oral y método para su fabricación | |
| KR20110057151A (ko) | 변색이 억제된 안정한 의약 제제 | |
| JP6243265B2 (ja) | ロスバスタチン含有医薬製剤 | |
| JP5415561B2 (ja) | Ｈｃｖポリメラーゼ阻害剤のプロドラッグを含む医薬組成物 | |
| JP6455611B2 (ja) | 経口投与用医薬組成物 | |
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 | |
| RU2008132846A (ru) | Композиции s-аденозилметионина для перорального применения | |
| EA039558B1 (ru) | Композиции в форме таблетки с замедленным высвобождением для перорального введения | |
| WO2014193528A1 (en) | Amorphous dosage forms and methods | |
| EP3263096A1 (en) | Pharmaceutical capsule composition of rivaroxaban | |
| CN109414402B (zh) | 用于制备具有存在于外层或局部的睾酮化合物的药物递送系统的方法以及这类药物递送系统 | |
| ES2373492T3 (es) | Composición farmacéutica con ingrediente activo atorvastatina. | |
| WO2012107090A1 (en) | Granulated composition comprising tadalafil and a disintegrant | |
| WO2021106004A1 (en) | Pharmaceutical composition of s-adenosylmethionine | |
| WO2015198225A1 (en) | Oral pharmaceutical composition of tofacitinib |